N. E. Kemeny - Concepedia

Author

N. E. Kemeny

Memorial Sloan Kettering Cancer Center

Also Known As

N E Kemeny, N KEMENY, N Kemeny, N. E. Kemeny, N. Kemeny, N.E. Kemeny, Nancey E. Kemeny

Publications

672

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center

About

N. E. Kemeny is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	257
2	Hepatology	3	3	60
3	Health Sciences	2	2	43
4	Gastroenterology	2	2	27
5	Immunology	1	1	182

N. E. Kemeny

Publications

506

Citations

H-Index

Page 1

	Year	Citations
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. Bruce D. Minsky, A. M. Cohen, N. E. Kemeny, Journal of Clinical Oncology	1992	203
Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer Leonard B. Saltz, Heinz‐Josef Lenz, Howard S. Höchster, Journal of Clinical Oncology Irinotecan-refractory Colorectal CancerImmunologyVersus Cetuximab/bevacizumabPathologyCrc Patients	2005	182
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! N. E. Kemeny PubMed Chemotherapy Effective TreatmentHepatologyMedicineLiver PhysiologyHepatobiliary Tumor	1992	33
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. Homer A. Macapinlac, N. E. Kemeny, Farhad Daghighian, PubMed	1996	30
Therapy of colorectal hepatic metastases. Jeanette M. Daly, N. E. Kemeny PubMed Surgical OncologyHepatologyGastrointestinal OncologyMedicineLiver Physiology	1986	17
Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. Farhad Daghighian, John L. Humm, Homer A. Macapinlac, PubMed	1996	16
Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder. Herr Hw, N. E. Kemeny, Alan Yagoda, PubMed Superficial Bladder TumorsUrologySurgical OncologyRecurrence RateGenitourinary Cancer	1978	15
Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion. Derek G. Power, Marinela Capanu, Dina Patel, Journal of Clinical Oncology Surgical OncologyGastroenterologyPathologyMultimodalityPharmacotherapy	2010	10

Page 1